Laurence Greenhill, MD
Laurence Greenhill is Ruane Professor of psychiatry
and pediatric psychopharmacology at Columbia University and a director
of the New York State Research Unit of Pediatric Psychopharmacology at
the New York State Psychiatric Institute and Attending at the Columbia
Presbyterian Medical Center. After obtaining his Bachelor of Arts Degree
at Columbia in 1963, and his Medical degree at Albert Einstein College
of Medicine, he served a one-year internship in pediatrics at Jacobi
Hospital. He then became a research associate working in the NIMH Lab of
Psychology with Paul Wender and David Rosenthal at the Clinical Center
in Bethesda, Maryland. In 1975, he was awarded an NIMH Research Career
Development Award in the psychopharmacology of child disorders.
Dr. Greenhill has served as the principal investigator of several
National Institute of Mental Health grants, he is the author of over120
published articles and has edited three books. From 2009 to 2011, he
served as the president of the American Academy of Child &
Adolescent Psychiatry (AACAP). While working on the NIMH Multimodal
Treatment Study of ADHD children (MTA Study), he coordinated the
development of its medication manual.
Session: SR1-Research Symposium II-MULTISITE RANDOMIZED CLINICAL
TRIALS: WHAT HAVE WE LEARNED ABOUT ADHD FROM THE MTA?; LITTLE CHILDREN,
BIG CHALLENGES: Treatment of Preschoolers with ADHD
Large clinical trials are the fastest and safest way to
discover effective treatments under controlled conditions for disorders
of childhood including Attention Deficit Hyperactivity Disorder (ADHD).
The NIMH-funded Multimodal Treatment of ADHD (MTA) study was a multisite
study designed to evaluate the leading treatments for ADHD, including
behavior therapy, medications, and the combination of the two in
elementary-aged children. The study's treatment phase lasted 14 months
and the observational longitudinal follow-up, currently in its 16th
year, at seven sites in the US and Canada, is ongoing and being funded
by NIDA. It is difficult to maintain followup over long periods of time
but longitudinal studies can provide valuable information on outcomes as
children mature and face other developmental problems. Longitudinal
studies also present analytic challenges, in particular with regard to
missing data and assessing the effect of treatment. The MTA follow-up
results will be presented in terms of substance abuse issues and other
measures of impairment that impact young adults diagnosed with ADHD as
children. This symposium will be presented in conjunction with Larry
Greenhill, MD who will be describing the PATS longitudinal study
outcomes.
Dr. Greenhill will provide an overview of the
diagnosis, evaluation, and treatment options for children with ADHD in
the preschool stage of development, between 3 years of age and 6 years
of age. He will discuss the findings and implications of the Agency for
Health Care Research and Quality (AHRQ's) lengthy review of published
treatments for ADHD that are the basis of the new American Academy of
Pediatrics Treatment Guidelines for ADHD.
| 
